Kala Pharmaceuticals, Inc.
KALADrugs in Pipeline
7
Phase 3 Programs
6
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
KPI-121 1% Ophthalmic Suspension dosed BID
Post Surgical Ocular Inflammation and Pain
Vehicle of KPI-121 0.25% Ophthalmic Suspension
Dry Eye Syndromes
KPI-121 Ophthalmic Suspension
Kerato Conjunctivitis Sicca
Vehicle
Blepharitis
KPI-121 0.25% Ophthalmic Suspension
Dry Eye Syndromes
KPI-121 1.0%
Ocular Infections, Irritations and Inflammations
KPI-121
Dry Eye Syndromes
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KPI-121 1% Ophthalmic Suspension dosed BID | Phase 3 | Post Surgical Ocular Inflammation and Pain | - | - |
Vehicle of KPI-121 0.25% Ophthalmic Suspension | Phase 3 | Dry Eye Syndromes | - | - |
KPI-121 Ophthalmic Suspension | Phase 3 | Kerato Conjunctivitis Sicca | - | - |
Vehicle | Phase 3 | Blepharitis | - | - |
KPI-121 0.25% Ophthalmic Suspension | Phase 3 | Dry Eye Syndromes | - | - |
KPI-121 1.0% | Phase 3 | Ocular Infections, Irritations and Inflammations | - | - |
KPI-121 | Phase 2 | Dry Eye Syndromes | - | - |
Dry Eye Syndromes
3 drugs in this indication
Kerato Conjunctivitis Sicca
1 drug in this indication
Post Surgical Ocular Inflammation and Pain
1 drug in this indication
Ocular Infections, Irritations and Inflammations
1 drug in this indication
Blepharitis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)